PEN stock sentiment todayPenumbra, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
PEN
Penumbra, Inc.Penumbra is dominating the high-growth thrombectomy market with its new Thunderbolt Aspiration System, driving significant margin expansion and top-line acceleration.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for PEN. Not financial advice.
Price · last 12 months
Gossip
The narrative centers on the successful rollout of the RED and Thunderbolt technologies, which are perceived as game-changers in stroke and pulmonary embolism treatment. Analysts are increasingly focused on the 'operating leverage story' as the company transitions from a high-burn growth phase to a highly profitable MedTech leader.
- ·Thunderbolt computer-aided aspiration launch
- ·Expansion into the venous thromboembolism (VTE) market
- ·Potential M&A target for larger MedTech conglomerates
Financial
PEN exhibits robust fundamentals with revenue growth consistently exceeding 20% and a significant shift toward positive GAAP net income. The balance sheet is clean with minimal debt and improving free cash flow.
- ·Revenue growth: 25%+ YoY
- ·Gross Margins: Strengthening toward 65%
- ·Forward P/E: High (~50x) but justified by EPS growth trajectory
- ·Net Debt: Low leverage relative to EBITDA
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Increasing competition from Medtronic and Inari in the VTE space
- ·High valuation multiples leave little room for quarterly misses
- ·Potential healthcare reimbursement changes for thrombectomy procedures
Peer temperature
How direct competitors stack up against PEN right now.
- NEUTRALNARIInari Medical
COLDER — specialized focus on venous disease lacks PEN's diversified neurovascular portfolio and broader computer-aided platform.
See full analysis → - COLDMDTMedtronic
COLDER — significantly slower revenue growth and legacy drag, despite a much lower valuation and larger dividend.
See full analysis → - HOTBSXBoston Scientific
HOTTER — matching PEN's momentum with a broader cardiovascular pipeline and superior scale at a more attractive PEG ratio.
See full analysis →
- PEN+0.3%
- NARI—
- MDT+3.6%
- BSX+1.3%
AI-generated analysis for informational purposes only. Not financial advice.